Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEU-411 SAD/MAD and Food Effect Study in Healthy Subjects
NCT05755191Phase 1Completed
- Sponsor
- Neuron23
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing NEU-411 with Placebo (2 arms). Primary endpoint: Safety and Tolerability (AEs, SAEs, vital signs, ECGs, labs) up to 7 days. Started May 2023; status: completed.
02
Drugs
NEU-411
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05755191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755191.